Evaluation of Serum Substance P Level in Chronic Urticaria and Correlation with Disease Severity

Javad Fadaee1, Maryam Khoshkhui1, Maryam Emadzadeh2, Seyed Isaac Hashemy3, Reza Farid Hosseini1, Farahzad Jabbari Azad1, Hamid Ahanchian4, and Fahimeh Lavi Arab5

1 Department of Immunology, Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 Clinical Research Unit, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 Department of Paediatric, Allergy and Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Department of Immunology, Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Received: 29 October 2018; Received in revised form: 18 May 2019; Accepted: 1 June 2019

ABSTRACT

Substance P (SP) is a neurotransmitter emitted from neurons that plays a role in the pathogenesis of itching conditions including chronic urticarial (CU). The present research aims to investigate the serum level of SP among CU patients and compare them with healthy subjects and explore how it correlates with the severity of urticaria.

The present research was conducted on 87 CU patients who visited the allergy clinic of Ghaem Hospital, Mashhad, Iran from October 2017 to June 2018. Besides, 86 healthy subjects were recruited as the control group. Background information of patient was collected including age, sex, duration of the disease and the co-occurrence of angioedema. SP serum level was measured in two groups by ELISA method. In the patients group, the autologous serum skin test (ASST) was performed along with the urticaria evaluation questionnaire include Urticaria Activity Score 7 (UAS7), Urticaria Control Test (UCT) and Chronic Urticaria Quality of Life (CU-Q2OL).

Among the patients, the SP serum level showed to be about two times higher than the healthy subjects ($p < 0.001$). SP showed to be increased as patients’ age grew ($p = 0.010$). In patients with a positive ASST, SP level was higher ($p = 0.012$). No correlation was found between SP and the presence of angioedema among patients. There was no correlation between the SP serum level and the scores obtained from urticaria evaluation questionnaires.

SP among CU patients was higher than healthy subjects. SP was also higher among female, older and positive ASST patients. The SP value was not correlated with the severity of urticaria, angioedema. In conclusion, Using SP antagonist drugs could be a potential treatment for chronic urticaria.

Keywords: Chronic urticaria; Substance P; Urticaria severity

Corresponding Author: Maryam Khoshkhui, MD; Department of Immunology, Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Tel: (+98 51) 3840 0000, E-mail: khoshkhuiM@mums.ac.ir
INTRODUCTION

Urticaria is characterized by the appearance of pruritic, erythematosus papules or plaques, with superficial swelling of the dermis. More than twenty percent of ordinary people in society experience hives at least once in their lives. If urticaria remains on the skin for a period of at least six weeks, it is called chronic urticaria (CU). CU usually affects more than one percent of the population, and in eighty percent, the cause is not known. Though CU is not a fatal disease, it tremendously affects the quality of life. Controlling the clinical symptoms of CU is also costly. Drugs such as antihistamines and corticosteroids often reduce the symptoms temporarily. Yet, in the long run, they can have certain adverse effects. Moreover, they do not work on all patients. Investigation of CU patients has shown that the presence of angioedema, more severe urticaria, positive autologous serum skin test (ASST) are correlated with a longer duration of the illness. The above-mentioned issues attest to the significance of the disease and recognition of the mechanisms involved so as to develop new and more efficient medical therapies.

As for the pathogenesis of CU, there have been numerous theories. Yet, none have been proven on an absolute basis. Though the majority of the related literature has looked into the autoimmunity theory, there are several investigations of mastocyte abnormalities of skin cells and basophils. A variety of reasons can lie behind the degranulation of mastocytes leading to the emergence of urticaria and itching. In an investigation, such neurotransmitters as SP showed to be involved in the degranulation of mastocytes and production of chemokines. In some other research, SP was found to be the most prevalent neurotransmitter released after a local trauma to the skin leading to the emergence of wheal and flare at the traumatic site. Substance P (SP) is a neuropeptide (neurotransmitter) with 11 amino acids which belongs to a family of peptides known as tachykinins. SP is released from certain neurons and belongs to the non-adrenergic non-cholinergic category (NANC). Once released, it is capable of activating some other inflammatory factors. It poses its effect through an axon reflex. SP is widely spread in the peripheral nervous system. It is not only present in neural tissues but also in such other tissues as skin. It from neurons or inflammatory cells such as macrophage, eosinophil, lymphocytes, and dendritic cells. It acts through binding to Neurokinin-1 receptor (NK1R) which is the main receptor. A body of research on patients afflicted with chronic itching skin diseases such as psoriasis showed that the rate of free plasma SP and its tissue as well as NK1R in patients suffering from itching is significantly higher than those without this problem. Moreover, an increase in the free plasma SP is closely related to the higher severity of such clinical symptoms as itching skin. Thus, these researchers suggested that probably SP and NK1R play a role in the pathophysiology of chronic itching skin diseases such as Psoriasis. In a body of research on chronic urticaria, first, no statistically significant difference was found between the SP level of those afflicted with CU and the control group. Newer investigations, however, reported the SP level many times as high. In some research, the level of SP showed to the with the severity of the disease. In another investigation, overregulation the in the NK1 receptor in eosinophil of CU patients. Besides, the rate of SP was higher than the normal control group.

Aprepitant drug, which is an antagonist of the NK1 receptor (SP receptor), is applied in the treatment of chemotherapy-resistant vomiting and its efficiency have been investigated. It has shown to be effective in treating chronic itching and CU resistant to therapy. If the correlation of SP and CU is proven and SP is targeted, its main receptor i.e. NK1 can be a new treatment for skin diseases that involve chronic itching including CU.

Due to the different result of studies, we design this project to evaluate the role of SP in CU.

PATIENTS AND METHODS

Data Collection

In the present research, two cross-sectional studies were conducted on 87 CU patients visiting the allergy clinic of Ghaem Hospital in Mashhad, Iran from October 2017 to June 2018. Full consent was obtained from the participant. Those included were patients diagnosed with CU by an allergist. Those with physical urticaria, those with systemic diseases and those with depression and anxiety were excluded.

So as to compare SP between patients and healthy population, a control group was used with 86 healthy subjects matched with the patient group in terms of age.
and sex, willing to take part in the study. The healthy have exclusion criteria like patients.

Questionnaire Completion
87 CU patients filled out a checklist to record demographic information such as age, gender, and duration of the disease.

In order to evaluate the effect of urticaria on their quality of life, the Persian version of (CU-QoL) (Chronic Urticaria Quality of Life) was used in this research. Completion of this questionnaire was followed by the Urticaria Activity Score7(UAS-7) questionnaire. The same physician completed the UAS-7 questionnaire for all patients.

The Urticaria Control Test (UCT) questionnaire was used to rate the extent to which urticaria was controlled in patients.

Sampling Procedure and Conducting ASST
Once the participants consented to undergo ASST, 5 cc blood sample was taken under sterilized conditions. The samples were then stored at room temperature for 30 minutes and when fully coagulated, they were segregated in a centrifuge device. A (31-gauge) syringe was used to inject 0.05 cc of patient’s serum, histamine (10 µg/mL) and normal saline (0.9%) as a positive and negative control to the front side of the forearm in a distance of 3-5 centimeters intradermal. Within 30 minutes of the test, the injection site was read. The negative control was supposed to be asymptomatic while the positive control was expected to be swollen with a red rash in the surroundings. ASST result would be taken as positive only when the injection site was 1.5 mm more swollen than the negative control site. The remaining blood serum was segregated and stored at -80 degrees centigrade until the test time. Then the S.P level was measured through ELISA kit (Made in Zell Bio GmbH, Germany, Cat No: ZB-11528C-H9648).

Ethical Considerations
Informed consent to take part in the research was obtained from the subjects. This research was approved by the Ethics Committee of Mashhad University of Medical Sciences (N. IR.MUMS.fm.REC.1396.610).

Statistical Analysis
The normality of data was checked through the Kolmogorov-Smirnov test. To compare normally-distributed variables in the two research groups, T-test was used and for compare abnormally distributed data, Mann-Whitney U-test was used for both groups. To compare quantitative variables across different age groups in terms of the type of distribution, ANOVA or Kruskal-Wallis were used.

Pearson or Spearman Correlation test was used to check whether there was a correlation between the variables. p-value was set at <0.05 to check the significance of findings. IBM SPSS, version 23 (IBM Corp., Armonk, N.Y., USA) was used to do all the analyses.

RESULTS

Participants’ Demographic Information
From 87 patients, 57 were female and 30 were male. There were 86 healthy subject participants, 56 of them were female and 30 were male. The age difference between the two groups was checked with Mann-Whitney U-test and the results showed that it is insignificant (p=0.926). The gender difference between the two groups was checked through the Chi-squared test and the results showed that it was not significant (p=0.956) (Table 1).

| Table 1. Demographics of chronic urticaria patients and normal control subjects in an of evaluation of serum Substance P levels | Chronic urticaria patients | Normal |
|---|---|---|
| n | 87 | 86 |
| Age (years) (mean±SD) | 35.72±12.00 | 35.81±12.30 |
| Sex | | |
| Male N(Percent) | 30(34.5) | 30(34.9) |
| Female N(Percent) | 57(65.5) | 56(65.1) |
Serum Evaluation of Substance P in a Study on Chronic Urticaria

The mean SP serum level of the patient group was 434.37±227.917 pg./mL, which was about twice as high as that of the healthy (238.21±116.980 pg./mL). Mann-Whitney U-test showed a statistically significant difference between the two research groups with this respect ($p<0.001$). Figure 1 indicates the SP serum level of all participants of both research groups.

SP Serum Level Compared in Terms of Patients’ Gender

In Group A (patients), the mean SP level of male participants was 400.13±184.954 and the mean of female participants was 452.39±247.188. In Group A, the difference between male and female was not statistically significant ($p=0.312$). In group B (control), the SP level of the male was estimated at 268.23±172.98 and that of the female group was 222.13±67.94 (Figure 2). In the control group, the two sexes showed no statistically significant divergence ($p=0.136$).

SP Serum Level Compared in Terms of Age

Pearson correlation test was run for all participants ($n=173$) which showed a statistically significant correlation between SP value and increase of age ($p=0.010$, $r=0.197$). In Group A (patients), the Spearman test was run which similarly showed a statistically significant correlation between increasing age and SP value ($p=0.004$, $r=0.307$) (Table 2).

SP Serum Level Compared in Terms of Patients’ Angioedema

Among 87 CU patients, 53 (61%) and 34 (39%) had respectively positive and negative test result. Among the former, the mean SP was significantly higher than the latter ($p=0.0012$) (Table 2). In terms of ASST size, among 53 CU patients with a positive ASST result, the mean diameter was 7.21±2.332 mm (min=3, max=13 mm).

Figure 1. Scatter plot of Substance P serum level of participants comparing Group A (urticaria patients) and Group B (normal control)
Figure 2. Substance P serum level in chronic urticaria patients group vs. healthy control group in terms of gender

**SP Serum Level Compared in Terms of the Duration of Disease**

The mean duration of CU was 36.85±56.981 months. No statistically significant correlation was found between the SP level and duration of the disease (p=0.57, r=0.062).

**SP Serum Level Compared in Terms of CU Severity Measured in Questionnaires**

Spearman correlation test was then run and found no statistically significant correlation between higher SP level and higher CU-Q2oL score (p=0.631), higher UAS7 score (p=0.898) and lower UCT score (p=0.092) (Table 3).

**ASST Result Compared with Urticaria Questionnaire Results**

To compare urticaria evaluation questionnaires as subjective measures and ASST result as an objective instrument of testing urticaria severity, positive and negative ASST subjects were compared that all results are showed in Table 4.

**ASST Size (mm) Compared with Questionnaire Results**

In the positive ASST group, the test size in millimeter was compared to the questionnaire results. Statistically significant correlations were found between UAS7 and Pruritus (p=0.042, r=0.280) in one hand and CU-Q2oL and Pruritus on the other (p=0.032, r=0.295).

Table 2. Substance P serum level in chronic urticaria patients across sex, age group, ASST result and angioedema

| Factor       | N (%)     | S.P (pg/mL) (Mean±SD) | p-value |
|--------------|-----------|------------------------|---------|
| Gender       |           |                        |         |
| Male         | 30 (34.5) | 400.13±184.95          | 0.312*  |
| Female       | 57 (65.5) | 452.39±247.19          |         |
| Age (years)  |           |                        |         |
| ≤20          | 7 (8)     | 412.86±307.78          | 0.054** |
| 21-40        | 52 (59.8) | 388.12±227.99          |         |
| 41-60        | 24 (27.6) | 540.46±189.59          |         |
| 60-80        | 4 (4.6)   | 110.3±436.758          |         |
| ASST         |           |                        |         |
| Positive     | 53 (61)   | 483.23±234.65          | 0.012*  |
| Negative     | 34 (39)   | 358.21±196.98          |         |
| Angioedema   |           |                        |         |
| Presence     | 36 (41.4) | 429.64±216.54          | 0.872*  |
| Absence      | 51 (58.6) | 437.70±237.69          |         |

ASST: Autologous Serum Skin Test, * T-test, **Kruskal-Wallis
Table 3. Spearman correlation of Substance P serum level and urticaria evaluation questionnaires data in chronic urticaria patients

| Test | Domain | UAS7 | UCT | Cu-Q2oL |
|------|--------|------|-----|---------|
|      | Total | Pruritus | Total | Pruritus | Swelling | Activities | Sleep | Limit | Look |
| S.P  | 0.898 | 0.599 | 0.957 | 0.092 | 0.631 | 0.260 | 0.318 | 0.980 | 0.971 | 0.499 | 0.795 |
| (pg/ml) | 0.014 | 0.057 | -0.006 | 0.182 | -0.052 | -0.122 | -0.108 | -0.003 | 0.004 | 0.073 | -0.028 |

ASST: Autologous Serum Skin Test, SP: substance P, * Spearman correlation
UAS7: Urticaria Activity Score 7, UCT: Urticaria Control Test, Cu-Q2oL: Chronic Urticaria Quality of Life

Table 4. Correlation of urticaria evaluation questionnaires data and Autologous Serum Skin Test result in chronic urticaria patients

| Test | Domain | UAS7 | UCT | Cu-Q2oL |
|------|--------|------|-----|---------|
|      | Total | Pruritus | Total | Pruritus | Swelling | Activities | Sleep | Limit | Look |
| A Positive | Mean | 26.45 | 12.60 | 13.85 | 5.50 | 62.77 | 7.60 | 4.24 | 16.02 | 14.50 | 7.79 | 12.60 |
| S.D | 10.63 | 5.49 | 5.75 | 2.68 | 17.05 | 1.84 | 2.39 | 5.71 | 4.87 | 2.71 | 4.71 |
| S Negative | Mean | 23.47 | 12.03 | 11.44 | 4.82 | 62.61 | 7.76 | 3.55 | 15.56 | 14.47 | 7.94 | 13.32 |
| S.D | 12.23 | 6.65 | 6.29 | 2.87 | 17.13 | 1.89 | 2.19 | 5.54 | 4.80 | 2.67 | 5.02 |
| p-value* | 0.232 | 0.626 | 0.043** | 0.261* | 0.967* | 0.611** | 0.166** | 0.712* | 0.971* | 0.749** | 0.500** |
| r | 0.248 | -0.487 | -2.020 | 0.269 | 0.967 | -0.511 | -1.385 | 0.710 | 0.971 | -0.320 | 0.5-7 |

ASST: Autologous Serum Skin Test, *T-test, ** Mann Whitney test, UAS7: Urticaria Activity Score 7
UCT: Urticaria Control Test, Cu-Q2oL: Chronic Urticaria Quality of Life

DISCUSSION

According to our knowledge, central histamine mediators often causes itching in CU patients. It is primarily released from the degranulation of mastocytes and basophils. Neurotransmitters such as SP, through degranulation of mastocytes and basophils, can cause itching and hives in people. The present research aimed to explore the role of SP in CU patients and the results indicated a higher level (twofold) of SP in CU patients in comparison with the healthy group.

In previous researches, only 4 other investigations explored the SP serum level in CU patients. Basak et al. had 57 CU patients along with 47 healthy subjects matched in terms of age and gender. They found a twofold increase in the CU patient group which was similar to the present finding. In another study, Metz et al. studied 118 CU patients compared with 30 healthy subjects. Similar to the present study, the SP level was higher in the CU group than the healthy (4 times as higher). In another research, Zheng et al reported a higher SP level in their CU group as compared to the control (3 times as higher). The only research which observed no difference between the SP level of the CU group and that of the healthy was conducted by Tedeschi et al with 117 patient subjects and 24 healthy individuals. They found no significant difference between these two groups. What was common between our research finding and that the research by Basak, Metz, and Zheng was the higher SP level in CU patients in comparison to healthy people. Contrary to the present research and others, the study by Tedeschi et al reported no statistically significant difference between the two groups. However, it is noteworthy that the experimental kits used in the newer researches including our study have been more sensitive.

In case the serum is segregated from blood after an hour or the cold chain is not stored in a freezer at the temperature of -80 degrees, the SP level is decreased. One advantage of the present research over others is the large health sample size (n=86) as compared to that of Tedeschi (n=24), Zheng (n=15) and Basak (n=46). This provided a more precise comparison of the healthy and patient groups. Moreover, in the present research, those with psychological disorders, anxiety or major depression were excluded from both groups; those with a physical disease other than CU which might have
induced an increase in SP level. Two research groups were matched in terms of age and gender. In the patient group, the SP showed to be higher among female participants and SP increase with the increase of age. In other investigations, SP level was not compared in terms of age or gender. As SP has been recognized as a factor involved in the severity of CU, positive ASST result is also considered a factor underlying the severity of CU and duration of disease. SP levels were compared in the two ASST result groups (positive and negative). The former group showed a significant higher SP level than the latter one. In Tedeschi’s investigation, 3 patients were positive ASST and marked as high SP level. In Basak’s research which looked into the correlation of ASST result and SP level, two groups showed no statistically significant divergence. Mind that the number of patient participants in the present research was higher than that of Basak research.

Due to the fact that angioedema is also a factor involved in the severity of CU, the presence of angioedema was also examined along with SP level. The result showed no statistically significant difference between those with and without angioedema in terms of SP level. This finding was similar to that of Metz. These groups were not compared in the related literature. There is a need for further research into the correlation of SP in CU patients and the prognostic factors of disease duration and CU severity (e.g. ASST, angioedema, duration of disease, etc.). SP level was taken as objective data of CU severity and its correlation was tested with the scores obtained from questionnaires as subjective data to test the severity of urticaria. No statistically significant correlation was found between UAS7, UCT, and CU-Q2oL scores and SP level. In the related literature, only Metz tested the correlation of SP level and UAS7 score and found a statistically significant correlation. None of the previous studies explored the correlation of SP serum level and duration of disease. In the present research, however, the correlation between the two was tested and showed to be insignificant. Thus, according to the present findings, SP is not a prognostic factor of CU severity and duration.

Another interesting point raised in the present research but absent in the related literature was the positive correlation between the questionnaire scores and positive ASST result. Statistically, a significant correlation was found between the pruritus domain of UAS7 and positive ASST result. So it is possible there is a correlation between positivity of ASST and severity of pruritus in chronic urticaria.

Similarly, statistically significant correlations were found between the induced diameter of ASST and the pruritus domain of UAS7 (p=0.042) and CU-Q2oL (p=0.032). This would show that for those with more itching (a higher pruritus score from UAS7 and CU-Q2oL), ASST would turn positive at a larger diameter.

The limitations of our study were the lack of evaluation of NK1 as a receptor of substance P and the small sample size. We suggest these performed in the future studies.

In light of the present findings, the serum level of SP in CU patients was twice as high as the healthy individuals. SP level showed to increase along with an increase in age. The serum level of SP was higher in the 40 to 60-year-old group and among the female gender. In patients with positive ASST result, SP level was higher than the negative ASST group. SP value showed no statistically significant correlation between the severity and duration of urticaria, angioedema and the evaluation scores of the disease.

ACKNOWLEDGMENTS

This article was adapted from a Research Project (Grant No. 960483) and subspecialty thesis written by Dr. Javad Fadaee, whose costs were funded by the Deputy of Research at Mashhad University of Medical Sciences.

REFERENCES

1. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133(5):1270-7.
2. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2)LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69(7):868-87.
3. Kocatürk E, Maurer M, Metz M, Grattan C. Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin Transl Allergy 2017; 7(1):1.
4. Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study.
Serum Evaluation of Substance P in a Study on Chronic Urticaria

of 139 patients. Allergy 2004; 59(8):869-73.
5. Kaplan A, Greaves M. Pathogenesis of chronic urticaria. Clinical and Experimental Allergy 2009; 39(6):777-87.
6. Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol 2008; 20(6):709-16.
7. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109(4):694-97.
8. Azimi E, Reddy VB, Pereira PJS, Talbot S, Woolf CJ, Lerner EA. Substance P activates Mas-related G protein-coupled receptors to induce itch. J Allergy Clin Immunol 2017; 140(2):447-953.e3.
9. Kulka M, Sheen CH, Tawoony BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008; 123(3):398-410.
10. Fuller RW, Conradson TB, Dixon CM, Crossman DC, Barnes PJ. Sensory neuropeptide effects in human skin. Br J Pharmacol 1987; 92(4):781-8.
11. Lisowska B, Lisowski A, Siewruk K. Substance P and chronic pain in patients with chronic inflammation of connective tissue. PLoS One; e0139206.
12. O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201(2):167-80.
13. Almeida T, Rojo J, Nieto P, Pinto F, Hernandez M, Martin J, et al. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004; 11(15):2045-81.
14. Puxeddu I, Praties F, Ribatti D, Migliorini P. Mediators of Inflammation and Angiogenesis in Chronic Spontaneous Urticaria: Are They Potential Biomarkers of the Disease? Mediators Inflamm 2017; 2017:4123694.
15. Amata B, El Nour H, Holst M, Theodorsson E, Nordling K. Expression of tachykinins and their receptors in plaque psoriasis with pruritus. Br J Dermatol 2011; 164(5):1023-9.
16. Tedeschi A, Lorini M, Asero R. No evidence of increased serum substance P levels in chronic urticaria patients with and without demonstrable circulating vasoactive factors. Clin Exp Dermatol 2005; 30(2):171-5.
17. Metz M, Krull C, Hawro TS, R., Groffik A, Stanger C, Staubach P, et al. Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. J Invest Dermatol 2014; 134(11):2833-6.
18. Basak P, Erturun I, Yuksel O, Kazanoglu O, Vural H. Evaluation of serum neuropeptide levels in patients with chronic urticaria. Indian J Dermatol Venereol Leprol 2014; 80(5):483.
19. Zheng W, Wang J, Zhu W, Xu C, He S. Upregulated expression of substance P in basophils of the patients with chronic spontaneous urticaria: induction of histamine release and basophil accumulation by substance P. Cell Biol Toxicol 2016; 32(3):217-28.
20. Wang W, Zhang H, Zheng W, He S. [Up-regulated expression of NK1R in eosinophil-enriched blood cells from patients with chronic spontaneous urticaria]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2017; 33(8):1108-12.
21. Sanger GI, Andrews PLR. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research. Front Pharmacol 2018; 9:913.
22. Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Allergy Clin Immunol 2011; 11(5):420-7.
23. Ständer S, Weisshaar E. Medical treatment of pruritus. Expert Opin Emerg Drugs 2012; 17(3):335-45.
24. Tey H, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J Dermatol 2011; 165(1):5-17.
25. Yosipovitch G, Bernhard JD. Chronic pruritus. N Engl J Med 2013; 368(17):1625-34.
26. Metz M, Ständer S. Chronic pruritus—pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010; 24(11):1249-60.
27. Ohanyan T, Schoepke N, Eirefelt S, Hoey G, Koopmann W, Hawro T, et al. Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical Aprepitant. Acta Derm Venereol 2018; 98(1-2):26-31.
28. Tavakol M, Mohammadnejad P, Baiardini I, Braido F, Gharagozlou M, Aghamohammadi A, et al. The persian version of the chronic urticaria quality of life questionnaire: factor analysis, validation, and initial clinical findings. Iran J Allergy Asthma Immunol 2014; 13(4):278-85.
29. Hawro T, Ohanyan T, Schoepke N, Metz M, Peveling-Oberhag A, Staubach P, et al. The Urticaria Activity Score—Validity, Reliability, and Responsiveness. J Allergy Clin Immunol Pract 2018; 6(4):1185-90.e1.
30. Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133(5):1365-72.
31. Sabroe R, Grattan C, Francis D, Barr R, Black AK,
Greaves M. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140(3):446-52.

32. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009; 64(9):1256-68.